论文部分内容阅读
慢性支气管炎急性加重严重影响患者的生活质量。目前已有研究证实50%～60%的急性加重患者与细菌感染有关,而经验性抗菌药物治疗已在临床得到广泛认可。既往的研究证实,莫西沙星对呼吸道常见病原体具有较好的抗菌活性,且在肺组织中的浓度较高。为了验证莫西沙星对慢性支气管炎急性加重患者的临床疗效,2004年R0bert等在《Chest》杂志上发表了M0SAIC研究。MOSAIC研究证实,莫西沙星对慢性支气管炎急性加重患者具有较好的短期临床疗效,及细菌清
Acute exacerbation of chronic bronchitis seriously affects the quality of life of patients. At present, studies have confirmed that 50% to 60% of patients with acute exacerbations are associated with bacterial infection, while empirical antibiotic therapy has been widely recognized in the clinic. Previous studies have confirmed that moxifloxacin has good antibacterial activity against common respiratory pathogens and high concentrations in lung tissue. To validate the clinical efficacy of moxifloxacin in patients with acute exacerbation of chronic bronchitis, Robert et al. Published the M0SAIC study in “Chest” in 2004. MOSAIC study confirmed that moxifloxacin in patients with acute exacerbation of chronic bronchitis have a better short-term clinical efficacy, and bacterial clearance